Opportunity to Submit Proposals for the Therapeutics for Rare and Neglected Diseases (TRND) Program

Notice Number: NOT-TR-12-007

Key Dates

Release Date:  July 3, 2012
Open Dates: August 1 to September 30, 2012

Issued by

National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)


The National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation, intends to publish an opportunity for research on the following:  The NCATS Therapeutics for Rare and Neglected Diseases (TRND) program performs preclinical and early clinical development of new drugs for rare and neglected diseases, and develops new technologies and paradigms to improve the efficiency of therapeutic development for these diseases.  The operational model of TRND is collaboration between intramural NCATS drug development scientists and partners having promising leads and disease/target knowledge but lacking the expertise or resources to develop these projects into clinical stage programs attractive to biopharmaceutical or other suitable organizations.  TRND is establishing collaborations with researchers in the public and private sectors to together “de-risk” Rare and Neglected disease drug development projects by accomplishing lead optimization through an FDA Investigational New Drug (IND) application and, when needed, proof-of-concept human studies. 

This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. 

This announcement for collaboration will not use NIH activity codes. Details of the opportunity are below.

Research Initiative Details

TRND collaborative projects will be initiated at any stage during preclinical development. Projects of interest will be at one of the following stages:

The TRND program will partner with academic laboratories, not-for-profit organizations, and for-profit companies.  Foreign organizations may also apply. Applications are made through the online grants management website, ProposalCentral (https://proposalcentral.altum.com/). Submitted research applications will be reviewed for scientific merit and technical feasibility, as well as program balance and availability of resources.  Successful applicants will collaborate with TRND to create and implement a therapeutic development project plan.  Note this is not a grant or contract program; no extramural funding will be provided.

For more information about the TRND program, including deadlines for current or upcoming opportunities, please visit the TRND webpage at http://trnd.nih.gov.

The application deadline for the current cycle of the program is September 30, 2012.


Please direct all inquiries to:

Andre M. Pilon, PhD
Division of Preclinical Innovation (DPI)
National Center for Advancing Translational Sciences (NCATS)
National Institutes of Health [c]
P: 301-827-2746
F: 301-827-2534

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy
NIH . . . Turning Discovery Into Health

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.